Contrafect Stock News

Northern Trust Corp decreased its stake in shares of ContraFect Co. (NASDAQ:CFRX) by 77.3% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 58,892 shares of the biotechnology companys stock after selling 200,660 shares during the period. Northern Trust Corps holdings in ContraFect were worth $259,000 at the end of the most recent []

ContraFect Corporation (NASDAQ:CFRX) traded at $3.41 at close of the session on Tuesday, 11/30/21, made an upward move of 5.90% on its previous days price. Looking at the stock we see that its previous close was $3.22 and the beta (5Y monthly) reads 0.97 with the days price range being $3.20 $4.2799. In terms What Does ContraFect Corporations (NASDAQ: CFRX) Future Hold? Read More »

ContraFect Co. (NASDAQ:CFRX) Equities research analysts at SVB Leerink raised their FY2021 EPS estimates for shares of ContraFect in a report released on Monday, November 15th. SVB Leerink analyst R. Ruiz now expects that the biotechnology company will post earnings per share of ($0.75) for the year, up from their prior forecast of ($0.95). []

ContraFect (NASDAQ:CFRX) released its quarterly earnings results on Monday. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts consensus estimates of ($0.28) by $0.15, Fidelity Earnings reports. Shares of NASDAQ:CFRX traded down $0.29 during trading hours on Wednesday, hitting $3.48. The companys stock had a trading volume of 86 shares, compared to its []

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2021.

Contrafect Corporation (NASDAQ:CFRX) Probability Sentiment SUMMARY Researchers have struggled with the problem of antibiotic resistance to bloodstream infection treatments for the past two decades. Approximately 70% of bacteria have developed a measure of resistance to at least one existing antibiotic. Yet because of robust antibiotic research 70 years ago, doctors []

YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA

Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA Data B

YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DL

CFRX is developing a medicine to treat bacterial infections without using an antibiotic. Phase 2 trials have shown outstanding data against MRSA infections, and reduced hospital time.

Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company's DLA portfolio

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA

YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs